Announcement • May 11
Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 26, 2026 Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 26, 2026. Announcement • May 09
Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2026 Results on May 11, 2026 Shin Nippon Biomedical Laboratories, Ltd. announced that they will report fiscal year 2026 results on May 11, 2026 Announcement • May 02
Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Apr 30, 2026 Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Apr 30, 2026. Agenda: To change the Company's representatives and to assign executive members as described below; and to consider AGM. Announcement • Dec 10
Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2026 Results on Feb 06, 2026 Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q3, 2026 results on Feb 06, 2026 Announcement • Aug 16
Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2026 Results on Nov 07, 2025 Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q2, 2026 results on Nov 07, 2025 Announcement • Jun 13
Shin Nippon Biomedical Laboratories, Ltd. to Report Q1, 2026 Results on Aug 05, 2025 Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q1, 2026 results on Aug 05, 2025 Announcement • May 08
Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 27, 2025 Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 27, 2025. Announcement • May 01
Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine Satsuma Pharmaceuticals Inc. and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved a 505(b)(2) New Drug Application (NDA) for Atzumi™ (dihydroergotamine (DHE)) nasal powder for the acute treatment of migraine with or without aura in adults. Atzumi was previously known as STS101. It is the second leading cause of disability worldwide in terms of time lost to disability and most common cause of disability among young women. The product is designed to provide patients an easy-to-use and easy-to-carry treatment option. The FDA approval for Atzumi is based on two clinical studies (Phase 1 PK trial and ASCEND Phase 3 open-label, long-term safety trial), which demonstrated fast absorption, rapid achievement of high DHE plasma concentrations, and sustained DHE plasma levels over time as well as safety and tolerability in subjects with migraine. Announcement • Mar 05
Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2025 Results on May 08, 2025 Shin Nippon Biomedical Laboratories, Ltd. announced that they will report fiscal year 2025 results on May 08, 2025 Announcement • Dec 19
Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2025 Results on Feb 05, 2025 Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q3, 2025 results on Feb 05, 2025 Announcement • Nov 26
Satsuma Pharmaceuticals, Inc. and Shin Nippon Biomedical Laboratories, Ltd. Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine with or Without Aura Satsuma Pharmaceuticals, Inc. and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. announced that the U.S. Food and Drug Administration (FDA) has accepted for review a resubmission to original new drug application (NDA) for the investigational product STS101 (dihydroergotamine nasal powder) for the acute treatment of migraine with or without aura as a complete response to their January 2024 action letter. The Prescription Drug User Fee Act (PDUFA) date is set as April 30, 2025. Almost 40 million people in the United States suffer from migraine, especially among working women in their 20s to 40s. The U.S. market for acute migraine medications is estimated to be over USD 1.0 Billion. Announcement • Sep 19
Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2025 Results on Nov 06, 2024 Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q2, 2025 results on Nov 06, 2024 Announcement • Jul 12
Shin Nippon Biomedical Laboratories, Ltd. to Report Q1, 2025 Results on Aug 06, 2024 Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q1, 2025 results on Aug 06, 2024 Announcement • May 10
Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 24, 2024 Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 24, 2024. Announcement • Mar 02
Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2024 Results on May 08, 2024 Shin Nippon Biomedical Laboratories, Ltd. announced that they will report fiscal year 2024 results on May 08, 2024 Announcement • Feb 02
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024 Shin Nippon Biomedical Laboratories, Ltd. provided consolidated earnings guidance for the year ending March 31, 2024. For the period, the company expects revenue of ¥26,190 million, Operating profit of ¥3,470 million, Profit attributable to owners of parent of ¥3,975 million or ¥95.47 basic per share. Announcement • Dec 06
Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2024 Results on Feb 02, 2024 Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q3, 2024 results on Feb 02, 2024 Announcement • Nov 07
Shin Nippon Biomedical Laboratories, Ltd. Announces Interim Dividend for the Year Ending 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Year Ending 2024 Shin Nippon Biomedical Laboratories, Ltd. announced that it was resolved at its Board of Directors' meeting November 7, 2023 that interim dividends of ¥20.00 shall be paid from retained earnings to shareholders on the record date of September 30, 2023. Effective date November 30, 2023.For the year ending 2024, the company expects to pay a dividend of JPY 30.00 per share. Announcement • Aug 30
Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2024 Results on Nov 07, 2023 Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q2, 2024 results on Nov 07, 2023 Announcement • Jun 17
Satsuma Pharmaceuticals and Shin Nippon Biomedical Laboratories, Ltd. Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to Be Presented at the American Headache Society's 65th Annual Scientific Meeting Satsuma Pharmaceuticals Inc. and its corporate parent, Shin Nippon Biomedical Laboratories Ltd. announced that three abstracts describing efficacy and safety results from the STS101 Phase 3 efficacy trial were selected for presentation at the American Headache Society's (AHS) 65th Annual Scientific Meeting. The 2023 meeting will be held in a hybrid virtual and in-person format at the JW Marriott in Austin, Texas from June 15 to June 18, 2023. Full abstracts are now available on the AHS website and will be published in the journal Headache®?. Announcement • Jun 09
Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA) from a group of sellers. Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) entered into an agreement to acquire the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA) from a group of sellers for $27.6 million on April 16, 2023. Under the terms of the transaction SNBL will acquire all the remaining shares of common stock of Satsuma through a tender offer, for a price of $0.91 per share in cash. In addition, SNBL will issue one non-tradeable CVR, represents the right to additional payments of up to $5.77 per share, in total in the event where Satsuma’s STS101 is approved by the FDA and commercialized, and SNBL achieves cumulative financial return objectives of up to $500 million. The purchase price will be funded from existing cash. Post the completion of the transaction, SNBL will hold 100% stake in Satsuma. The merger agreement also provides that the payment of a $905,136 termination fee will be payable by Satsuma to Shin Nippon. As part of the merger, Satsuma will terminate the employment of each of John Kollins, President and Chief Executive Officer of the Company, and Tom O’Neil, Chief Financial Officer of the Company, effective as of the closing of the Offer. Prior to the closing, such executive officers shall remain in their current positions with their current compensation.The transaction is subject to the tender of a majority of Satsuma’s outstanding shares, minimum cash condition and other customary closing conditions. The transaction has been unanimously approved by the Board of Directors of both SNBL and Satsuma. The tender offer period is planned from April 2023 to May 2023, with the initial period of the tender offer to commence within 15 business days following the execution of definitive agreement. The expiration of the tender offer is on June 5, 2023. American Stock Transfer & Trust Company acted as transfer agent and depository bank to Satsuma. Joshua M. Dubofsky of Latham & Watkins LLP acted as legal advisor to Satsuma. Ian B. Edvalson of Wilson Sonsini Goodrich & Rosati P.C. acted as legal advisor to Wilson Sonsini Goodrich & Rosati P.C. Lazard acted as lead financial advisor and Houlihan Lokey Capital, Inc. acted as financial advisor and fairness opinion provider to Satsuma. D.F. King & Co., Inc. acted as information agent to Satsuma.Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA) from a group of sellers on June 8, 2023. The Offer expired at the end of June 5, 2023. Total of 21,979,704 Shares were validly tendered and not validly withdrawn pursuant to the Offer, which represented approximately 66.0618% of the fully-diluted capitalization of Satsuma. 
